M&A activity Potential cross-sell opportunities with Mylan’s expanded asset base and recent acquisitions, such as the Famy Care deal and Agila Specialties assets, to accelerate product line diversification and manufacturing capabilities in injecting and specialty drugs.

Expansion footprint Leverage Mylan’s investment in Indian manufacturing capacity and regional growth in Southern Asia to propose local supply chain partnerships, contract manufacturing, and regulatory-compliant distribution deals for injections and sterile products.

Scale potential With a workforce in the mid thousands and revenue in the lower multi-millions, position solutions that optimize manufacturing efficiency, quality management, and cost-effective outsourcing to support gradual scale for growing product portfolios.

Tech enablement Target modernization opportunities around cloud, email, and web infrastructure (AWS, Office 365, Nginx) to offer secure, scalable digital transformation services, cold-chain logistics tech, and eClinical/ERP integrations.

Competitive context Capitalize on the competitive landscape by aligning offerings with mid-cap pharma players like Mylan’s peers, presenting value through strategic partnerships in generic portfolios, fill-finish capabilities, and global distribution access.